Successful treatment of cardiac sarcoidosis with infliximab.

Abstract

To the Editor: The clinical presentation of cardiac sarcoidosis may include arrhythmias, pericardial or valvular disease, congestive heart failure, or ventricular aneurysms1. Cardiac sarcoidosis is regarded as an indication for corticosteroid therapy2. Immunosuppressive agents are often combined with corticosteroids to reduce adverse effects. Anti-tumor necrosis factor-α (anti-TNF-α) therapy has been used to treat refractory sarcoidosis3, and TNF-α expression has been documented at sites where sarcoid granulomas are observed, and plays a critical role in granuloma formation4. Thus, anti-TNF-α therapy should result in suppression of disease manifestation and progression. The use of infliximab in patients with cardiac sarcoidosis has been described…